Status:
COMPLETED
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when admini...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy males and females according to the following criteria
- Body Mass Index 18.5 to 29.9 kg/m2 (incl.)
- Exclusion criteria:
- Any finding of the medical examination (including Blood Pressure, Pulse Rate and electrocardiogram) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
Exclusion
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01211197
Start Date
October 1 2010
Last Update
August 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1276.5.1 Boehringer Ingelheim Investigational Site
Biberach, Germany